No Data
No Data
J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $48
Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
William Blair Remains a Buy on Beam Therapeutics (BEAM)
Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment
Express News | Reported Sunday, Beam Therapeutics Showcases Proof-Of-Concept Non-Human Primate Data For ESCAPE, A Non-Genotoxic Antibody-Based Conditioning Strategy For Sickle Cell Disease, At ASH 2024
No Data